

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

May 27, 2020  
Date of Report (date of earliest event reported)

**Corcept Therapeutics Incorporated**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**000-50679**  
(Commission File Number)

**77-0487658**  
(I.R.S. Employer Identification No.)

**149 Commonwealth Drive, Menlo Park, CA 94025**  
(Address of Principal Executive Offices) (Zip Code)

**(650) 327-3270**  
Registrant's telephone number, including area code

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	CORT	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 5.07. Submission of Matters to a Vote of Security Holders

On May 27, 2020, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2021 annual meeting of stockholders and until their respective successors are elected and qualified, 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020, and 3) to approve, by non-binding advisory vote, the compensation of our named executive officers.

A total of 114,601,708 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 17, 2020 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 102,335,382. The voting on the three matters is set forth below:

Proposal 1 — Election of Directors. The following directors were elected to serve until our 2021 annual meeting of stockholders and until their respective successors are elected and qualified.

<b>Director</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
James N. Wilson	75,262,397	7,739,657	19,333,328
Gregg Alton	82,244,170	757,884	19,333,328
G. Leonard Baker, Jr.	80,395,568	2,606,486	19,333,328
Joseph K. Belanoff, M.D.	82,307,866	694,188	19,333,328
David L. Mahoney	65,881,782	17,120,272	19,333,328
Kimberly Park	82,787,147	214,907	19,333,328
Daniel N. Swisher, Jr.	81,507,667	1,494,387	19,333,328

Proposal 2 — To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.

For	98,806,154
Against	3,483,197
Abstain	46,031
Broker Non-Votes	N/A

Proposal 3 — To approve, by non-binding advisory vote, the compensation of our named executive officers.

For	76,887,975
Against	5,808,900
Abstain	305,179
Broker Non-Votes	19,333,328

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS INCORPORATED**

Date: May 29, 2020

By: /s/ Charles Robb

Name: Charles Robb

Title: Chief Financial Officer and Secretary